Clinical trial

Replicor Compassionate Access Program

NCT05683548

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2025-02-17

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Viral Hepatitis Bunresolved

Viral Hepatitis Dunresolved

Cirrhosis, Liverunresolved

Decompensated Cirrhosisunresolved

Ascites Hepaticunresolved

Varices, Esophagealunresolved

Hepatocellular Carcinomaunresolved

Interventions

REP 2139-MgDRUG

Tenofovir Disoproxil FumarateDRUG · verified · RxNorm: tenofovir disoproxil fumarate

Pegylated interferon alpha2aDRUG

Sponsors & collaborators

Replicor Inc.lead sponsor

Mapped research locations

MontpellierFrance2 ToulouseFrance1 MarseilleFrance1 IstanbulTurkey (Türkiye)1 ViennaAustria1 LilleFrance1 RennesFrance1 LimogesFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05683548 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.